NEW YORK (GenomeWeb) – Aldatu Biosciences is expanding its team in anticipation of initiating end-user evaluations next year of its genetic test for antiviral-resistant strains of HIV in select countries in Southern Africa.
The Cambridge, Massachusetts-based startup, which recently became a registered public-benefit corporation, also received funding from a foundation focused on child health and is hoping to attract additional mission-driven investors in the future.